Cancer Res Treat.  2012 Sep;44(3):157-165.

Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study

• The Gastrointestinal Pathology Study Group of Korean Society of Pathologists
• Cho MY
• Kim JM
• Sohn JH
• Kim MJ
• Kim KM
• Kim WH
• Kim H
• Kook MC
• Park DY
• Lee JH
• Chang H
• Jung ES
• Kim HK
• Jin SY
• Choi JH
• Gu MJ
• Kim S
• Kang MS
• Cho CH
• Park MI
• Kang YK
• Kim YW
• Yoon SO
• Bae HI
• Joo M
• Moon WS
• Kang DY
• Chang SJ

Abstract

PURPOSE
As a result of various independently proposed nomenclatures and classifications, there is confusion in the diagnosis and prediction of biological behavior of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A comprehensive nationwide study is needed in order to understand the biological characteristics of GEP-NETs in Korea.
MATERIALS AND METHODS
We collected 4,951 pathology reports from 29 hospitals in Korea between 2000 and 2009. Kaplan-Meier survival analysis was used to determine the prognostic significance of clinicopathological parameters.
RESULTS
Although the GEP-NET is a relatively rare tumor in Korea, its incidence has increased during the last decade, with the most significant increase found in the rectum. The 10-year survival rate for well-differentiated endocrine tumor was 92.89%, in contrast to 85.74% in well differentiated neuroendocrine carcinoma and 34.59% in poorly differentiated neuroendocrine carcinoma. Disease related death was most common in the biliary tract (62.2%) and very rare in the rectum (5.2%). In Kaplan-Meier survival analysis, tumor location, histological classification, extent, size, mitosis, Ki-67 labeling index, synaptophysin expression, lymphovascular invasion, perineural invasion, and lymph node metastasis showed prognostic significance (p<0.05), however, chromogranin expression did not (p=0.148). The 2000 and 2010 World Health Organization (WHO) classification proposals were useful for prediction of the prognosis of GEP-NET.
CONCLUSION
The incidence of GEP-NET in Korea has shown a remarkable increase during the last decade, however, the distribution of tumors in the digestive system differs from that of western reports. Assessment of pathological parameters, including immunostaining, is crucial in understanding biological behavior of the tumor as well as predicting prognosis of patients with GEP-NET.

Keyword

Gastro-enteropancreatic neuroendocrine tumor; Incidence; Prognosis; Pathology

MeSH Terms

Biliary Tract
Carcinoma, Neuroendocrine
Digestive System
Humans
Incidence
Intestinal Neoplasms
Korea
Lymph Nodes
Mitosis
Neoplasm Metastasis
Neuroendocrine Tumors
Pancreatic Neoplasms
Population Characteristics
Prognosis
Rectum
Stomach Neoplasms
Survival Rate
Synaptophysin
World Health Organization
Intestinal Neoplasms
Neuroendocrine Tumors
Pancreatic Neoplasms
Stomach Neoplasms
Synaptophysin

Figure

• 

  Fig. 1 Distribution of 4,951 gastroenteropancreatic neuroendocrine tumors according to the organ system.

• 

  Fig. 2 Distribution of gastroenteropancreatic neuroendocrine tumors according to diagnosis by 2000 and 2010 classification.WDET, well-differntiated endocrine tumor; WDEC, well-differentiated endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma/small cell carcinoma; MEEC, mixed exocrine-endocrine carcinoma; MEC, metastatic endocrine carcinoma; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma.

• 

  Fig. 3 Site distribution of gastroenteropancreatic neuroendocrine tumors in Korea according to the 2000 WHO classification. The most common tumor is WDET in rectum. WHO, World Health Organization; WDET, well-differntiated endocrine tumor; MEC, metastatic endocrine carcinoma, MEEC, mixed exocrine-endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma/small cell carcinoma; WDEC, well-differentiated endocrine carcinoma.

• 

  Fig. 4 Changes in incidence of gastroenteropancreatic neuroendocrine tumors in Korea during the last decade according to the number of annual diagnosis.

• 

  Fig. 5 Changes in annual incidence of gastroenteropancreatic neuroendocrine tumors in each site during the last decade.

• 

  Fig. 6 Changes in incidence of gastroenteropancreatic neuroendocrine tumors in Korea during the last decade according to the 2000 WHO classification of tumors. WHO, World Health Organization; WDET, well-differntiated endocrine tumor;WDEC, well-differentiated endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma/small cell carcinoma; MEEC, mixed exocrine-endocrine carcinoma; MEC, metastatic endocrine carcinoma.

• 

  Fig. 7 Site distribution of gastroenteropancreatic neuroendocrine tumors according to the survival. Mean survival time is the longest in stomach neuroendocrine tumor (154.42±7.74 months) and the shortest in biliary tract neuroendocrine tumors (44.32±6.02 months). Disease related death is most common in hepatobiliary tract.

• 

  Fig. 8 Five- and 10-year survival rate according to the 2000 (A) and 2010 WHO classification of NET (B). According to the 2000 WHO classification, the difference of 10 year survival rate between NET G1 and NET G2 is more distinct than the difference between WDET and WDEC. WHO, World Health Organization; NET, neuroendocrine tumor; WDET, well-differntiated endocrine tumor; WDEC, well-differentiated endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma/small cell carcinoma; MEEC, mixed exocrine-endocrine carcinoma; MEC, metastatic endocrine carcinoma; NEC, neuroendocrine carcinoma.

Reference

1. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004; 1014:13–27. PMID: 15153416.

2. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009; 90:162–166. PMID: 19060454.

3. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39:707–712. PMID: 20664470.

4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 2010. 4th ed. Lyon: International Agency for Research on Cancer.

5. Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007; 451(Suppl 1):S9–S27. PMID: 17684761.

6. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010; 39:753–766. PMID: 20664473.

7. Washington MK, Tang LH, Berlin J, Branton PA, Burgart LJ, Carter DK, et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. Arch Pathol Lab Med. 2010; 134:176–180. PMID: 20121603.

8. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–1474. PMID: 20180029.

9. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010; 34:300–313. PMID: 20118772.

10. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010; 39:713–734. PMID: 20664471.

11. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449:395–401. PMID: 16967267.

12. Fritz A, Percy C, Jack A, Shanmugaratnam S, Sobin L, Parkin DM, et al. International classification of diseases for oncology (ICD-O). 2000. 3rd ed. Geneva: World Health Organization.

13. Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004; 240:117–122. PMID: 15213627.

14. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010; 21:1794–1803. PMID: 20139156.

15. Rothenstein J, Cleary SP, Pond GR, Dale D, Gallinger S, Moore MJ, et al. Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol. 2008; 31:64–70. PMID: 18376230.

16. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010; 45:234–243. PMID: 20058030.

17. Lee H, Choi J, An JS, Kim H, Shin BK, Kim A, et al. The clinicopathological characteristics of gastrointestinal neuroendocrine tumors: an analysis of 65 cases. Korean J Pathol. 2007; 41:149–157.

18. Chetty R. An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology. Arch Pathol Lab Med. 2008; 132:1285–1289. PMID: 18684027.

19. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 2010. 7th ed. New York: Springer.

20. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol. 2005; 19:491–505. PMID: 16183523.

21. Williams ED, Siebenmann RE, Sobin LH. Histological typing of endocrine tumours. 1980. Geneva: World Health Organization.

22. Colonoscopy Study Group of Korean Society of Coloproctology. Clinical characteristics of colorectal carcinoid tumors. J Korean Soc Coloproctol. 2011; 27:17–20. PMID: 21431092.

23. Jernman J, Valimaki MJ, Louhimo J, Haglund C, Arola J. The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology. 2012; 95:317–324. PMID: 22327359.

24. Hirata I, Akutagawa H, Nishikawa T, Yasumoto S, Sanomura M, Egashira Y, et al. Clinicopathological study of colorectal carcinoid tumor, focusing on the indication for endoscopic mucosal resection (EMR). Stormach Intest. 2005; 40:182–193.

25. Tabata H, Matsumoto T, Kuwano Y, Yao T, Iida M. Rectal carcinoid tumor 10 mm in diameter accompanied by multiple liver metastases, report of a case. Stormach Intest. 2005; 40:215–220.